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http://dx.doi.org/10.1016/j.ccr.2013.06.014SUMMARYAccelerated glucose metabolism is a common feature of cancer cells. Hexokinases catalyze the first
committed step of glucose metabolism. Hexokinase 2 (HK2) is expressed at high level in cancer cells, but
only in a limited number of normal adult tissues. Using Hk2 conditional knockout mice, we showed that
HK2 is required for tumor initiation and maintenance in mouse models of KRas-driven lung cancer, and
ErbB2-driven breast cancer, despite continued HK1 expression. Similarly, HK2 ablation inhibits the
neoplastic phenotype of human lung and breast cancer cells in vitro and in vivo. Systemic Hk2 deletion is
therapeutic in mice bearing lung tumors without adverse physiological consequences. Hk2 deletion in lung
cancer cells suppressed glucose-derived ribonucleotides and impaired glutamine-derived carbon utilization
in anaplerosis.INTRODUCTION
Accelerated glucose metabolism under aerobic conditions is
one of the hallmarks of cancer cells. The elevated glucose meta-
bolism is required to provide sufficient amounts of metabolic in-
termediates to support anabolic processes, such as nucleic
acid, lipid, and protein synthesis in the rapidly dividing cancer
cells (for review, see Lunt and Vander Heiden, 2011; Schulze
and Harris, 2012). The dependency of cancer cell proliferation
on accelerated glucose metabolism distinguishes them from
their normal counterparts and could render them more vulner-Significance
The feasibility of systemic targeting glycolytic enzymes for can
first committed step of glucose metabolism, are attractive can
highly expressed in glycolytic cancer cells and not in norma
approaches, we showed that HK2 is required for tumor initiatio
To emulate drug therapy, we showed that systemic whole-bo
tively targets cancer cells. Thus, we provided a proof of concep
for cancer therapy.able to the disruption of glucose metabolism. Therefore, cancer
cells could be selectively targeted by the disruption of intracel-
lular glucose metabolism. However, it unclear whether it is
feasible to inhibit enzymatic activities required for glucose meta-
bolism, at the organism level, and to selectively target cancer
cells without adverse physiological consequences. The identifi-
cation of isoform-specific contributors to cancer cell glucose
metabolism that could be selectively targeted to disadvantage
cancer cells without compromising systemic homeostasis or
corresponding metabolic functions in normal cells could make
such an approach feasible.cer therapy is unproven, but hexokinases, which catalyze the
didate targets for such intervention. Targeting HK2, which is
l cells, could selectively target cancer cells. Using genetic
n andmaintenance, and its deletion is therapeutic for cancer.
dy deletion of Hk2 in the mouse is feasible and that it selec-
t, using genetic approaches, that HK2 is an attractive target
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Hexokinase 2, Is a Therapeutic Target for CancerHexokinases (HKs) catalyze the first committed step in
glucose metabolism, i.e., the ATP-dependent phosphorylation
of glucose (Glc) to yield glucose-6-phosphate (G6P). Four major
hexokinase isoforms, encoded by separate genes, are ex-
pressed in mammalian tissues: HK1, HK2, HK3, and HK4 (also
known as glucokinase) (Robey and Hay, 2006). By catalyzing
the phosphorylation of Glc to G6P, hexokinases promote and
sustain a concentration gradient that facilitates glucose entry
into cells and the initiation of all major pathways of glucose utili-
zation. Therefore, hexokinases influence both themagnitude and
the direction of glucose flux within cells. Although the four HKs
sharemany common biochemical properties, their intrinsic enzy-
matic activity and their tissue distribution distinguish them from
each other. HK1, HK2, and HK3 are high-affinity isoforms, but
HK3 is inhibited by physiological concentrations of glucose
(Wilson, 2003). The high-affinity hexokinases are inhibited by
excess of G6P. Glucokinase is a low-affinity hexokinase, which
is not inhibited by G6P and is mainly expressed in liver and
pancreas. The two high-affinity hexokinases, HK1 and HK2,
are associated with mitochondria and were also implicated in
cell survival (Gottlob et al., 2001; Majewski et al., 2004). HK1 is
constitutively expressed in most mammalian adult tissues.
HK2, however, although abundantly expressed in embryonic tis-
sues, is expressed at high levels only in a limited number of adult
tissues, such as adipose, skeletal, and cardiac muscles (Wilson,
2003). However, cancer cells express high levels of HK2 (Mathu-
pala et al., 2001; Shinohara et al., 1994), which distinguishes
them from the normal cells and is, at least in part, responsible
for the accelerated glucose flux. The high level of HK2 expres-
sion and activity in glycolytic cancers are manifested by the
use of positron emission tomography (PET) to visualize tumors.
PET is used following injection of the labeled glucose analog,
[18F]fluoro-2-deoxyglucose (FDG), which is then taken up by
glycolytic cancer cells and phosphorylated by hexokinase to
form FDG-phosphate, which can be detected by PET. The phos-
phorylation by hexokinase is required for the retention of FDG in
the cancer cells. Given its selective overexpression in cancer
cells and its restricted distribution of expression in normal adult
tissues, HK2 constitutes an attractive potential selective target
for cancer therapy.
The studies described here are aimed at elucidating the role of
HK2 in tumor initiation and maintenance of KRas-driven non-
small cell lung cancer (NSCLC) and ErbB2-driven breast cancer
and to provide a proof of concept that HK2 can be systemically
deleted for cancer therapy with no adverse physiological
consequences.
RESULTS
HK2 Is Required for Oncogenic Transformation
Germline deletion of Hk2 in the mouse causes early embryonic
lethality (Heikkinen et al., 1999). Therefore, we used Hk2flox/flox
(Hk2f/f)mice for our studies (Figure S1A available online). Mouse
embryonic fibroblasts (MEFs) generated from these mice were
immortalized with dominant-negative p53 (DNp53) and were
subjected to adenovirus expressing Cre recombinase (Ad-Cre)
infection to deleteHk2 and to generateHk2/MEFs (Figure 1A).
To determine the requirement of HK2 for oncogenic transforma-
tion, the cells were subjected to oncogenic Ras. Interestingly,214 Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc.oncogenic Ras expression markedly elevated HK2 expression
(Figure 1A), and both PI3K and MAPK signaling contributes to
this elevated expression (Figure S1B). Hk2 deletion impaired
oncogenic transformation as measured by anchorage-indepen-
dent growth on soft agar (Figure S1C). Notably, Hk2 deletion by
Cre was not complete, and a residual expression of HK2 is still
observed especially in the presence of activated Ras (Figure 1A).
Furthermore, the cells also express HK1 and therefore total
hexokinase activity in the Ras-transformed cells was reduced
by approximately 70% and glucose consumption was reduced
by approximately 50% (Figures 1B and 1C), and without a
compensatory expression of the glucose transporter, GLUT1
(Figure S1D). However, the deletion of Hk2 after the expression
of oncogenic Raswas sufficient to profoundly reverse oncogenic
transformation (Figure 1D). Finally, Hk2 deletion in oncogenic
Ras-transformed cells markedly impaired tumor growth in vivo
in xenograft assays (Figure 1E). Re-expression of WT HK2 in
Hk2/ MEFs restored their susceptibility to tumorigenesis
in vivo, whereas a kinase-dead mutant of HK2 could not
(Figures 1F, S1E, and S1F). Thus, both HK2 expression and
activity are required for oncogenic transformation of MEFs and
cannot be compensated by the presence of physiological level
of HK1.
HK2 Is Required for Lung and Breast Cancer
Development in Mouse Models
The results described above used MEFs, which normally ex-
press HK2. However, although HK2 is expressed at relatively
high levels in embryonic tissues, the major expression in adult
tissues is largely restricted to muscle and adipose (Wilson,
2003). To address the role of HK2 in tumorigenesis in adult tis-
sues in vivo, we used mouse models of NSCLC induced by acti-
vated KRas, and a mouse model for breast cancer induced by
activated ErbB2/Neu. KRas is an oncogenic driver of human
NSCLC and ErbB2/neu is an oncogenic driver of human breast
cancer. We first isolated lung tissues from control WT or
tumor-bearing KRas mutant mice. Normal lungs express HK1
but do not express detectable HK2 protein. In contrast, HK2 pro-
tein expression was markedly elevated in the individual tumors
isolated from KRas-induced mice lung tumors, without any sig-
nificant change in HK1 protein level (Figure 2A). We therefore
used KRasLSL-G12D mice, a well-characterized mouse model for
NSCLC (Jackson et al., 2001). We crossed KRasLSL-G12D mice
with Hk2f/f mice to generate KRasLSL-G12D;Hk2f/f mice. In these
mice, exposure to Ad-Cre, through intubation, induces activated
KRas expression with concomitant deletion of Hk2. Control
KRasLSL-G12D and KRasLSL-G12D;Hk2f/f mice were subjected to
Ad-Cre and were killed 4 months after exposure to Ad-Cre.
Lung tissues were isolated to determine tumor burden, individual
tumor size, tumor number, proliferation, and apoptosis. Total
tumor burden was markedly reduced in KRasLSL-G12D;Hk2f/f
mice compared with KRasLSL-G12D mice (Figures 2B and 2C).
Moreover, the average tumor size was significantly smaller in
KRasLSL-G12D;Hk2f/f mice (Figure 2D). The average number of
lesions was reduced inKRasLSL-G12D;Hk2f/fmice but is not statis-
tically significant (Figure 2E). This effect of Hk2 deletion is largely
due to impaired proliferation asmeasured by BrdU incorporation
(Figure 2F). No significant increase in cell death, as measured
by caspase 3 cleavage, was observed (data not shown). We
Figure 1. HK2 Is Required for Oncogenic
Transformation
(A) Immortalized Hk2f/f MEFs following infection
with either Ad-Cre or Ad-LacZ, as a control, were
established and stably infected with a retrovirus
expressing oncogenic HRasV12. Cell extracts
were subjected to immunoblotting with anti-HK2
or anti-HK1 antibodies. Control undeleted cells
are denoted Hk2f/f and Hk2-deleted cells are
denoted Hk2/.
(B) Relative total hexokinase activity in Ras-
transformed Hk2f/f and Hk2/ MEFs.
(C) Relative glucose consumption in Ras-
transformed Hk2f/f and Hk2/ MEFs. Data
represent the percentage of glucose consumed
by Ras-transformed Hk2/MEFs compared with
Ras-transformed Hk2f/f MEFs after culturing for
18h and after adjusting for cell number.
(D) Average number of colonies generated by
Ras-transformed Hk2f/f and Hk2/ MEFs after
6 weeks of growth on soft agar.
(E) The effect of Hk2 deletion on tumorigenesis
in vivo. Ras-transformed Hk2f/f and Hk2/ MEFs
were injected subcutaneously into athymic nude
mice, and tumor size was calculated. Left:
representative tumor images of Ras-transformed
Hk2f/f and Hk2/ MEFs (scale bars 1 cm). Right:
average tumor size formed by Ras-transformed
Hk2f/f andHk2/MEFs (n = 4 tumors per each cell
type).
(F) The requirement of HK2 activity for tumori-
genesis in vivo. Ras-transformed Hk2/ MEFs
stably expressing WT or kinase-dead HK2, and
Ras-transformed Hk2f/f or Hk2/ control MEFs
were subjected to tumorigenesis in vivo as
described in E. Tumor size was calculated when
tumor size of control Ras-transformedHk2f/fMEFs
reached approximately 2 cm3 (n = 4 tumors per
each cell type).
(B–F) Data are mean ± SEM. ***p % 0.001. **p%
0.01. *p% 0.05. See also Figure S1.
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lung tumorigenesis. Tumors isolated from the KRasLSL-G12D;
Hk2f/f mice had residual expression of HK2, possibly due to
incomplete deletion, but no significant change in HK1 expression
was observed (Figure 2G). Taken together, these results suggest
that small lesions could be developed, even at very low level of
HK2 expression, but cannot be further developed into large
tumors. This was manifested by the striking effects of Hk2
deletion not only on KRasLSL-G12D mouse tumor burden, but
also on overall mortality. Kaplan-Meier survival curves reveal
profoundly delayedmortality of KRasLSL-G12D;Hk2f/fmice relative
to KRasLSL-G12D mice. In addition, more than 50% of HK2-
deficient KRasLSL-G12D;Hk2f/f mice were still alive 250 days fol-
lowing Ad-Cre exposure, a time point corresponding to 100%
mortality in HK2-expressing KRasLSL-G12D mice (Figure 2H).
We found that HK2 expression is also markedly elevated in
tumor tissues of mouse models of breast cancer, whereas it is
hardly detected in the normal mammary gland (Figure 3A). Wetherefore crossedMMTV-Neu-IRES-Cre (MMTVNIC)mice, which
coexpress activated Neu and Cre in the mammary gland with
Hk2f/f mice.MMTVNIC transgenic mice develop mammary gland
tumors with a complete penetrance (Ursini-Siegel et al., 2008).
As shown in Figure 3B, all theMMTVNIC (NIC;Hk2+/+) mice devel-
oped tumors with an onset of less than 20 weeks. Hk2 deletion
delayed the onset of tumor appearance and had a striking
effect on the incidence of tumors. At the time when 100% of
NIC;Hk2+/+mice developed tumors more than 60% ofMMTVNIC;
Hk2f/f (NIC;Hk2f/f) mice remained tumor free (Figure 3B). Further-
more, when tumors isolated from NIC;Hk2f/fmice were analyzed
for HK2 expression, they display comparable levels of HK2
with that observed in tumors derived fromNIC;Hk2+/+ (Figure 3C).
Thus, these tumors were originated from cells in which Hk2
was not efficiently deleted, suggesting that if, Hk2 would be
completely deleted in all the mammary cells, which express
activated Neu, the outcomes would have been even more
substantial.Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc. 215
Figure 2. HK2 Is Required for the Development of Oncogenic Kras-Driven NSCLC in Mice, and Its Deletion Extends the Life Span of These
Mice
(A) Tissue lysates from lungs of control KRasLSL-G12D mice or from tumors in lungs of KRasLSL-G12D mice after exposure to Ad-Cre were subjected to immu-
noblotting with anti-HK2 or anti-HK1 antibodies. Ad-Cre-treated KRasLSL-G12D and KRasLSL-G12D;Hk2f/f mice are denoted as Hk2+/+ and Hk2/, respectively.
(B) Sixteen weeks after Cre instillation to induce lung tumors, lung sections were subjected to H&E staining (scale bar 4 mm).
(C) Percentage tumor burden calculated from the H&E-stained sections of tumor-bearing lungs from KRasLSL-G12D mice (n = 8) or KRasLSL-G12D;Hk2f/f
mice (n = 8).
(legend continued on next page)
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Figure 3. HK2 Is Required for the Development of ErbB2/Neu-Driven
Mammary Tumors in Mice
(A) Immunoblot showing HK2 expression in tissue lysates from normal
mammary gland or mammary gland tumors isolated from MMTVNeuT and
MMTVPyMT mice.
(B) Kaplan-Meier curves of percentage tumor-free survival of MMTVNIC
(NIC;Hk2+/+) andMMTVNIC;Hk2f/f (NIC;Hk2f/f) mice. The p value was calculated
by log-rank test.
(C) Immunoblot showing HK2 expression in tumor lysates obtained from mice
with the indicated genotypes.
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that HK2 is required for both oncogenic KRas-driven lung
tumorigenesis and ErbB2-driven mammary gland tumorigenesis
in vivo.(D) Average tumor size per lungs of KRasLSL-G12D (n = 7) or KRasLSL-G12D;Hk2f/f (
(E) Tumor number calculated from the H&E-stained sections of tumor-bearing lu
(F) Average number of BrdU-positive cells per field as calculated from 403 magn
Hk2f/f lungs from three different mice were used for this analysis.
(G) Immunoblot showing HK2 and HK1 expression in tumors obtained from KRa
(H) Kaplan-Meier survival curves of lung tumor-bearingKRasLSL-G12D orKRasLSL-G
survival (t = 50), for the indicated genotypes were calculated by log-rank test.
(C–F) Data are mean ± SEM.HK2 Ablation Reverses Tumorigenesis In Vitro and
In Vivo of NSCLC and Breast Cancer Cells
To determine whether HK2 expression is also elevated in human
patient samples, we analyzed tumor tissue microarray (TMA) of
human NSCLC. Immunohistochemical staining showed that
HK2 expression is markedly and significantly elevated in tumor
samples of NSCLC compared with adjacent normal lung tissue
and that the higher HK2 expression level is correlated with the
pathological grade of the tumors (Figure 4A). To further assess
the prognostic significance of high HK2 expression in human
patients, we analyzed a previously generatedmicroarray dataset
comprising a large number of human NSCLC patients (Shedden
et al., 2008). We found that high HK2 expression is significantly
(p = 0.0025) associated with poor prognosis of these individuals
(Figure S2A). We therefore examined the ability of HK2 ablation
to reverse tumorigenicity of human lung cancer cell lines. For
this purpose, we have generated lentiviral vector expressing
HK2-specific shRNA, which efficiently silenced HK2 in the
human cancer cells (Figure 4B). This shRNA was selected from
several other shRNAs as the most efficient one (Figure S2B).
Expression of rat HK2, which is resistant to silencing by the
human HK2 shRNA, restores the proliferation of the knockdown
cells, indicating that the effect of the shRNA is specific to HK2
(Figure S2C). Interestingly, overexpression of HK1 could also
restore proliferation to some extent (Figure S2D). All the NSCLC
cell lines tested express HK1 (Figure 4B), but the knockdown of
HK2 significantly and markedly decreased the proliferation of
three human NSCLC cell lines tested despite HK1 expression
(Figure S2E). Importantly, the knockdown of HK2 markedly
attenuated the ability of all NSCLC cell lines tested to grow in
an anchorage-independent manner (Figure 4C). We then ex-
pressed doxycycline (DOX)-inducible HK2 shRNA in H460 cells
(Figure 4D). The inducible knockdown reduced the proliferation
rate of these cells to a similar extent as the noninducible knock-
down (Figure S2F) with a modest increase in cell death (Fig-
ure S2G). The cells were then inoculated into nude mice. When
tumors reached approximately 65mm3 in volume, experimental
mice groups were subjected to DOX in the diet. As shown in Fig-
ure 4E, the induction of HK2 silencing by DOX substantially
attenuated the growth of the tumors. We ruled out the possibility
that the attenuated tumor growth is due to a potential DOX
toxicity because a similar attenuated tumor growth occurred
when we compared the tumor growth of cells expressing DOX-
inducible HK2 shRNA with that of cells expressing DOX-induc-
ible scrambled shRNA after DOX treatment (Figure S2H). Tumors
isolated from treated and untreated mice, at the endpoint of the
study, showed no significant change in HK2 level (Figure 4F),
suggesting that the cells, which gave rise to these tumors,
escaped the knockdown. We therefore analyzed the tumors
one week after DOX treatment and found a substantial silencingn = 8) mice.
ngs from KRasLSL-G12D (n = 8) or KRasLSL-G12D;Hk2f/f (n = 8) mice.
ification of tumor sections. At least 10 fields of KRasLSL-G12D or KRasLSL-G12D;
sLSL-G12D or KRasLSL-G12D;Hk2f/f lungs.
12D;Hk2f/fmice after exposure to Ad-Cre at 8weeks of age; p values andmedian
Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc. 217
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(Figure 4H), further supporting that the tumors observed at a later
stage were derived from cells that escaped the knockdown of
HK2. Because of the remarkable effect of HK2 silencing on tumor
growth and because the tumors that appeared after induction of
HK2 silencing escaped silencing, we predict that a more effec-
tive HK2 silencing would completely block tumor growth.
To determine whether HK2 ablation could reverse the tumori-
genic phenotype of the murine lung cancer cells, we crossed
KRasLA2-G12D mice (Johnson et al., 2001) with Hk2f/f mice and
generated cell lines derived from the lung tumors developed in
these mice. These primary tumor cell lines expressed HK2 like
their tumor counterparts (data not shown). The lung cancer cell
lines were infected with either adenovirus expressing LacZ or
Cre. Efficient deletion ofHk2was observed in the cells (Figure 4I).
Hk2 deletion inKRasLA2-G12D cells markedly reduced the prolifer-
ation of the cells (Figure 4J).
As in NSCLC, HK2 expression is markedly elevated in human
breast cancer tissues, and its expression level is correlated with
the pathological stage of the tumors (Figure 5A). Again, the anal-
ysis of an available human breast cancer dataset (van de Vijver
et al., 2002) showed that high HK2 expression is significantly
associated with high mortality of the patients (Figure S3A). We
therefore silenced HK2 expression in multiple breast cancer
cell lines (Figure 5B) and found that it markedly affected their
ability to grow in an anchorage-independent manner (Figure 5C).
Moreover, the knockdown of HK2 in MDA-MB-453 breast
cancer cells, which display ERBB2 amplification, impaired their
ability to form orthotopic tumors in nude mice (Figure 5D). We
concluded that HK2 ablation could reverse the tumorigenicity
of human breast cancer cells in vitro and in vivo.
To determine whether HK2 ablation could reverse tumorigen-
esis of ErbB2-driven mammary tumors, we crossed MMTVNeuT
mice (Muller et al., 1988) with Hk2f/f mice and isolated mammary
tumor cell lines from these mice. Hk2 was deleted by Ad-Cre
(Figure S3B), and early passage HK2-proficient or HK2-deficient
cells were subjected to orthotopic transplantation. As shown in
Figure 5E, the deletion of Hk2 dramatically attenuated tumor
growth in vivo. The impaired ability of HK2-deficient cells to
form tumors is due to impaired proliferation as verified by a
decrease in BrdU incorporation (Figures 5F and 5G). Thus,Figure 4. HK2 silencing reverses tumorigenesis of NSCLC cells in vitro
(A) Left: immunohistochemical staining of HK2 expression in representative hum
disease (scale bar 1 mm). Right: quantification of HK2 staining intensity in accor
nontumor, 22 grade 1, 44 grade 2, and 14 grade 3. Box plots represent the 25th to
and the minimum value.
(B) Immunoblot showing the level of HK2 and HK1 protein expression in a panel
shRNA as control.
(C) Equal numbers of either control or HK2 knockdown cells were subjected to so
the mean of three independent experiments ± SEM (p% 0.002).
(D) Immunoblot showing HK2 protein level in NCI-H460 cells expressing an induci
for 96 hr before analysis.
(E) NCI-H460 cells (0.75 3 106) were injected subcutaneously into athymic nude
(n = 8) or normal chow diet (n = 7), and tumor growth was followed until tumor s
(F) At the end of the experiment described in E, tumor lysates were subjected to
(G) Immunoblot showing HK2 protein levels in tumor lysates harvested 1 week a
(H) BrdU incorporation in tumors 1 week after exposure to DOX diet.
(I) Deletion of Hk2 in NSCLC cell line derived from KRasLA2-G12D;Hk2f/f mice.
(J) Cell proliferation after Hk2 deletion in the NSCLC cell line derived from KRasL
(C, E, H, and J) Data are mean ± SEM. See also Figure S2.these results clearly show that HK2 ablation could reverse the
tumorigenicity of tumor cells derived from mouse mammary
tumors.
In summary, these results provided strong evidence that the
induction of HK2 expression is essential for the neoplastic
phenotype of lung and breast cancer cells and that HK2
ablation reverses the tumorigenicity of these cancer cells
in vitro and in vivo. This was observed in mouse models of
NSCLC and breast cancer and was recapitulated in human
NSCLC and breast cancer.
Systemic Hk2 Deletion in Adult Mice Does Not Cause an
Overt Phenotype but Reduces Tumor Burden of Lung
Cancer
As was shown above, HK2 is expressed at high levels in cancer
cells but is hardly detectable in the corresponding normal tissues
from which they were derived. HK2 is expressed as the predom-
inant isoform in only a limited number of adult tissues, such as
fat, muscles, and heart (Figure S4A), andmice with 50% deletion
ofHk2 do not show an overt phenotype except of mildly impaired
glucose homeostasis in response to exercise and high fat diet
(Fueger et al., 2003).
The next question that needed to be addressed is whether
systemic whole-body ablation of HK2 can reverse tumorigenesis
without eliciting adverse physiological consequences. We there-
fore crossed Hk2f/f mice with mice, harboring the ubiquitously
expressed tamoxifen-inducible Cre (UBCCreERT2) (Ruzankina
et al., 2007) to systemically delete Hk2 in all adult tissues fol-
lowing exposure to tamoxifen. The generated Hk2f/f;UBCCreERT2
mice were treated with tamoxifen when they were 2 months old
as previously described (Ruzankina et al., 2007). As shown in
Figure 6A, Hk2 was effectively deleted in adult tissues express-
ing high levels of HK2, although the deletion was incomplete in
some of the tissues. Surprisingly, global HK2 ablation in adult
mice was well tolerated, and HK2-deficient mice were indistin-
guishable from control mice both morphologically and in terms
of growth and body weight (Figure S4B). We then examined
whether these mice display impaired glucose homeostasis.
Mice globally deficient for HK2 had normal glucose and insulin
levels under both fed and fasting conditions and responded nor-
mally to glucose tolerance testing (Figures S4C–S4E). Theseand in vivo
an NSCLC patient samples TMA correlates with the pathological grade of the
dance with the pathological grade. TMA samples analyzed are as follows: 20
75th percentiles (boxes) with median and the whiskers represent the maximum
of human NSCLC cells stably expressing either shRNA targeting HK2 or LacZ
ft-agar assay, and colonies were counted after 3 weeks. Data are expressed as
ble control or HK2 shRNA. The cells were exposed to vehicle or 500 ng/ml DOX
mice. When tumor size reached 65 mm3, mice were fed DOX-containing diet
ize reached 1.5–2 cm3.
immunoblotting with anti-HK2 antibodies.
fter exposure to the DOX diet.
A2-G12D;Hk2f/f mice.
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Figure 5. HK2 Silencing Reverses Tumorigenesis of Breast Cancer Cells In Vitro and In Vivo
(A) Left: representative images of immunohistochemical staining of HK2 in human breast cancer sample TMA, showing low expression in the stroma and benign
tumors and high expression in cancer samples (scale bar 0.5 mm). Right: quantification of HK2 staining intensity in the stroma, benign tumors, and cancer
samples: stroma (n = 4), benign (n = 8), tumor (n = 15). Box plots represent the 25th to 75th percentiles (boxes) with median, and the whiskers represent the
maximum and the minimum value.
(B) Immunoblot showing HK2 protein level in a panel of human breast cancer or transformed mammary cells stably expressing either shRNA targeting HK2 or
LacZ shRNA as control.
(C) Equal numbers of control or HK2 knockdown cells were subjected to soft-agar assay, and colonies were counted after 3 weeks. Data are expressed as the
mean of three independent experiments ± SEM (p% 0.003).
(legend continued on next page)
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development of any overt distinguishing morphological or meta-
bolic phenotypes.
To test whether systemic ablation of HK2 can reverse
tumorigenesis in vivo, we used the KRasLA2-G12D NSCLC mouse
model, in which lung tumors are developed with an early
onset and complete penetrance (Johnson et al., 2001). We
intercrossed Hk2f/f;UBCCreERT2 and KRasLA2-G12D mice to
generate KRasLA2-G12D ;UBCCreERT2, KRasLA2-G12D;Hk2f/f, and
KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice. These mice were injected
with tamoxifen after tumor lesion onset, at 2 months of age, to
systemically delete Hk2. Mice were killed 4 months later, and
lungs were analyzed for tumor burden (see schematic diagram
in Figure 6B). There was no significant difference in tumor burden
among tamoxifen-treated control groups KRasLA2-G12D;Hk2f/f
and KRasLA2-G12D ;UBCCreERT2 treated with tamoxifen (Fig-
ure S4F). However, tumor burden was substantially decreased
after Hk2 deletion in KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice
compared with KRasLA2-G12D;Hk2f/f mice (Figures 6C and 6D).
Likewise, tumor numbers per mouse were significantly
decreased after Hk2 deletion (Figure 6E). Tumor size distribution
showed that the majority of tumors in the tamoxifen-treated
KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice are relatively smaller (Fig-
ure 6F). Because of the stochastic nature of the inducible Cre
system, HK2 expression was still detectable in some tumors
arising in tamoxifen-treated KRasLA2-G12D;Hk2f/f;UBCCreERT2
mice, especially in larger size tumors (Figure 6G). Therefore,
it is likely that a subgroup of the tumors that appeared in
tamoxifen–injected KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice arose
from cell lineages that escaped complete Hk2 deletion.
However, in tamoxifen-injected KRasLA2-G12D;Hk2f/f;UBCCreERT2
mice, both the small and the larger tumors display markedly
impaired proliferation (Figures 6H and S4G), indicating that
even reduced HK2 expression attenuates tumor growth.
To characterize the tumors immediately after HK2 loss,
we injected tamoxifen to 16- to 18-week-old mice, at a stage
in which most of the tumors express very high levels of
HK2 (data not shown). One week after the last dose of
tamoxifen injection, we analyzed the tumors for BrdU incorpo-
ration. We found that the tumors derived from the tamoxifen-
injected KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice incorporated
substantially less BrdU compared with control mice (Fig-
ure S4H). These results further support that HK2 is required
for the proliferation of established lung tumor cells in vivo.
Importantly, taken together, these observations provided
compelling genetic evidence that HK2 could be an attractive
target for lung cancer therapy, without adverse physiological
consequences.(D) Equal numbers of MDA-MB-453 cells stably expressing either HK2 shRNA or
athymic nude mice. Tumor growth was followed.
(E) Cells of cell line derived from a mammary tumor of MMTVNeuT;Hk2f/f mice we
NeuT;Hk2f/f or NeuT;Hk2/ cells. The cells were then injected orthotopically in fe
until tumor size reached approximately 2 cm3. Bottom: representative images of
(F) Immunoblot showing HK2 and HK1 protein levels in tumor protein lysates fro
(G) Quantification of BrdU incorporation in tumor sections derived from the tum
calculated from (403 magnification) of the tumor tissue sections. At least ten fi
quantification.
(D, E, and G) Data are mean ± SEM. See also Figure S3.HK2 Is Required for Ribonucleotide Synthesis, the
Serine Biosynthesis Pathway, and the Flow of Carbons
from Glycolysis into the TCA Cycle and Fatty Acid
Synthesis in KRasG12D- NSCLC Cells
As demonstrated above, HK2 is specifically elevated during
tumorigenesis and is required for tumorigenesis despite persis-
tent HK1 expression. Both HK1 and HK2 are capable of phos-
phorylating glucose into G6P, which is then utilized and required
in multiple fundamental metabolic processes, which are essen-
tial for glycolytic and rapidly dividing cells. These include
glycolysis, either coupled to, or independent of, mitochondrial
oxidative metabolism, nucleotide biosynthesis via the pentose
phosphate pathway (PPP), amino acid biosynthesis, lipogenesis,
and hexosamine biosynthesis required for glycosylation. It is
therefore possible that the induction of HK2 expression in
cancer cells, which already express HK1, is required for the
high metabolic demand of the cancer cells. To test this possibil-
ity, we have established cell lines derived from lung tumors of
KRasLA2-G12D;Hk2f/f mice. For long-term studies, the cell lines
were first infected with retrovirus expressing DNp53. Two
isogenic pairs of cell lines were chosen for further analyses
and were subjected to adenovirus infection with either Ad-
LacZ or Ad-Cre to deleteHk2.Hk2 deletion (Figure S5A) impaired
the proliferation of the cells (Figure S5B).
To investigate the possibility of differential utilization of
glucose upon Hk2 deletion, we then conducted metabolomics
analyses of the cells using liquid chromatography tandem
mass spectrometry (LC/MS/MS). Although the abundance of
many metabolites was decreased by Hk2 deletion in both cell
lines (Figure 7A), the most statistically significant decrease was
found in the levels of fructose 1, 6 bisphosphate (F1,6BP) and
phosphoserine (p-Ser). Differential rates of biosynthesis were
then investigated by the exchange of glucose in culture medium
with stable isotopes of glucose and analysis of resultant
labeling patterns. Upon feeding with U-13C6 glucose, incorpora-
tion of glucose-derived pentose units into ribonucleotides was
impaired by Hk2 deletion (Figure 7B). However, the labeling
patterns of nonoxidative PPP intermediates, including ribose
5-phosphate, were not affected (Figure S5C).
In a previous study in a mouse model of KRas-dependent
pancreatic ductal adenocarcinoma, it was shown that oncogenic
KRas induces nucleotide biosynthesis largely through the
enhancement of the nonoxidative branch of the PPP (Ying
et al., 2012). We therefore speculate that, in Hk2 deleted cells,
the PPP is in a mode that does not support high generation of
ribonucleotides through the nonoxidative branch of the PPP
but rather maintains G6P/F6P equilibrium and NADPH derived
from the oxidative PPP. Indeed, NADP and NADPH levels werecontrol shRNA were injected into the fat pad of the mammary glands of female
re infected with either Ad-GFP or Ad-Cre-GFP to delete Hk2 and to generate
male athymic nude mice (six mice per group), and tumor growth was followed
tumors (scale bar, 1 cm).
m individual tumors shown in (E).
ors described in E. The average number of BrdU-positive cells per field was
elds from three different tumors per each mouse genotype were used for the
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Figure 6. Systemic Deletion of Hk2 in the Mouse Is Therapeutic for Oncogenic KRas-Driven NSCLC
(A) Immunoblot showing HK2 and HK1 protein expression in tissues isolated from either Hk2f/f or Hk2f/f;UBCCreERT2 mice 2 weeks after final tamoxifen injection.
(B) Schematic illustration of the experiment described in (C)–(H).
(C) Representative images of H&E staining of whole-mount lung sections prepared from either KRasLA2-G12D;Hk2f/f or KRasLA2-G12D;Hk2f/f;UBCCreERT2 lungs,
12 weeks after injection of tamoxifen at 8 weeks of age. Individual tumors are indicated by arrows (scale bar, 4 mm).
(D) Percentage tumor burden as calculated from the H&E sections of tumor-bearing lungs from eitherKRasLA2-G12D;Hk2f/f orKRasLA2-G12D;Hk2f/f;UBCCreERT2mice
at 20 weeks of age and after injection of tamoxifen at 8 weeks of age (n = 8 per group).
(E) Tumor numbers calculated from the H&E-stained sections of tumor-bearing lungs from either KRasLA2-G12D;Hk2f/f or KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice
(n = 8 per group).
(legend continued on next page)
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of G6P shunted to the oxidative PPP is not affected by Hk2 dele-
tion, as demonstrated by equivalent fractions of labeled lactate
containing 13C1 upon feeding with 1,2-
13C2 glucose (Lee et al.,
1998) (Figure 7C). In this experiment, singly labeled lactate is
assumed to have been derived exclusively from the oxidative
PPP, where one of the labels is lost as 13CO2. Taken together,
these strongly indicate that the oxidative branch of the PPP is
not impaired in the absence of HK2. Despite Hk2 deletion, the
pool sizes of G6P/F6P are not significantly decreased. There-
fore, it is possible that, in the absence of HK2, more nonoxidative
PPP intermediates are shunted to regenerate F6P instead of
being used to generate ribonucleotides. However, this possibility
requires further experimental validation. Consistent with the
reduced diversion of glucose into ribonucleotides synthesis in
the absence of HK2, we found a significant reduction in the incor-
poration of both U-14C6-labeled glucose and 1-
14C1-labeled
glucose, the latter of which labels nucleotides derived from the
nonoxidative branch of the PPP (among other routes), into
DNA and RNA in the absence of HK2 (Figure S5D).
Flow of carbon from glycolysis into the TCA cycle is also
reduced upon Hk2 knockout, as demonstrated by the reduced
fraction of doubly labeled citrate/isocitrate and cis-aconitate
(Figures 7D and S5E). The pool sizes of citrate/isocitrate and
cis-aconitate were also significantly reduced. Notably, a
reduced fraction of doubly labeled acetyl-CoA (AcCoA) is also
observed. Because cytosolic and mitochondrial pools may not
be differentiated by this study, AcCoA observed is a summation
of the functions of both pyruvate dehydrogenase and ATP citrate
lyase, the latter of which is en route to fatty acid biosynthesis.
Reduced doubly labeled AcCoA reflects a reduction in one or
both of these fluxes.
Glutamine-Derived Carbon Incorporation into TCA
Cycle Intermediates Is Reduced in KRasG12D-NSCLC
Cells following Hk2 Deletion
Oncogenic Ras-transformed cells are highly dependent on the
availability of glutamine, which is heavily incorporated into TCA
cycle intermediates in these cells (Gaglio et al., 2011). We
therefore examined Hk2 deletion for the ability to alter glutamine
requirements in oncogenic Ras-expressing cells. Interestingly,
we found that exogenous glutamine restriction markedly
reduced proliferation of both KRasG12D-NSCLC cells and MEFs
transformed by oncogenic Ras. In contrast, proliferation of these
cells followingHk2 deletionwas not further affected by glutamine
restriction (Figure S5F).
Across all conditions tested, it is apparent that the pool sizes of
TCA cycle intermediates and thosemetabolites directly adjacent
are reduced by Hk2 deletion (Figure 7E). To further investigate
fluxes throughout the TCA cycle, cells were fed U-13C5-labeled
glutamine. Upon conversion to glutamate (Glu), then a-ketoglu-
tarate (aKG), all five 13C-labeled carbons from glutamine (Gln)
are maintained. Observed raw signal from the LC/MS/MS indi-(F) Size distribution of tumors developed in the lungs of either KRasLA2-G12D;Hk2
(G) Immunoblot showing HK2 and HK1 protein levels in tumor lysates extracted a
tumorswere randomly selected for analysis; lanes 5 and 6: tumor size < 0.025mm2
(H) Quantification of Ki67 staining of the same size groups of tumors derived from
(D, E, and H) Data are mean ± SEM. See also Figure S4.cates that the 5-labeled forms of Gln andGlu are relatively similar
between control and Hk2 deletion, whereas a drastic drop is
observed in the 5-labeled signal for aKG, suggesting that the
transamination reaction of Glu to aKG is impaired by Hk2
deletion (Figure 7F). Although this reaction can be catalyzed
by many enzymes, including glutamate dehydrogenase, gluta-
mate-aspartate aminotransferase, and alanine transaminase, it
was previously reported that, in cells expressing high 3-phos-
phoglycerate dehydrogenase, approximately half of aKG is
generated by the transamination catalyzed by phosphoserine
aminotransferase (PSAT1) in the serine biosynthesis pathway
(Possemato et al., 2011). Because Hk2 deletion reduced the
abundance of p-Ser (Figure 7A), it is possible that the effect of
HK2 on the serine biosynthesis pathway also affects the utiliza-
tion of Gln into aKG. Although the pool size of total unlabeled
aspartate was not significantly changed upon deletion of Hk2
(Figure 7E), the pool size of 13C4 aspartate derived from Gln
was reduced (Figure 7F).
Decarboxylation of aKG, derived from U-13C5 Gln, to succi-
nate, fumarate, malate, and aspartate, yields 13C4 carbons
upon the first turn of the TCA cycle and 13C2 upon the second
turn (Figure S5G). In the first turn of the TCA cycle, reduced
flux into succinate, malate and aspartate is reflected in the
decreased pool sizes, whereas a similar fraction of the pool is
labeled by carbon derived from glutamate (Figure 7G). Upon
the second turn, a greater difference in the fractional 13C2-
labeled form is observed, again demonstrating a reduced rate
of TCA cycling upon Hk2 deletion. Each of these patterns is
mirrored in citrate/isocitrate (Figure 7G).
Interestingly, we observed an increase in 13C5- labeled citrate
derived from U-13C5 Gln in the absence of HK2 (Figure 7H), indi-
cating reductive carboxylation is a larger contributor to the
citrate pool in Hk2-deleted cells. Consistent with increased
13C5 citrate derived from reductive carboxylation, we observed
a higher fraction of AcCoA in cells fed with U-13C5 Gln (Figures
7I and S5G). Taken together with the finding that glycolytic
contribution to the AcCoA pool is decreased, these results indi-
cate that, in the absence of HK2, reductive carboxylation
partially compensates for the impaired glycolytic flux into citrate,
AcCoA, and presumably fatty acid biosynthesis.
Taken together, these results suggest that the TCA cycle is
attenuated in the absence of HK2. Corresponding reductions
in citrate abundance, derived from Glc, and TCA cycle interme-
diates, derived from Gln, could be both a cause and a conse-
quence of reduced Gln incorporation, as anaplerosis and
cataplerosis are always tightly matched to maintain TCA cycle
carbon balance (Owen et al., 2002). Regardless of the explana-
tion, these results suggest that the high HK2 expression induced
by oncogenic Ras is an indirect determinant of Gln utilization.
Therefore, it is possible that proliferation of oncogenic Ras-
transformed cells in which Hk2 is deleted is not further inhibited
by Gln restriction due to a reduced anaplerotic role for Gln-
derived carbon in these cells.f/f or KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice (n = 6 per group).
t 20 weeks of age, and after tamoxifen injection at 8 weeks of age. Lanes 1–4:
; lanes 7–9: tumor size 0.3–0.05mm2; lanes 10–14: tumor size 0.05–0.025mm2.
either KRasLA2-G12D;Hk2f/f or KRasLA2-G12D;Hk2f/f;UBCCreERT2 mice.
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Signature alterations in themetabolism of cancer cells have been
recognized for more than three-quarters of a century (Robey and
Hay, 2009; Vander Heiden et al., 2009). Because the high flux of
glucose utilization distinguishes many cancer cells from their
normal counterparts, many of these studies provide rationales
for targeting certain glycolytic enzymes for cancer therapy. How-
ever, because of the fundamental biological importance of
glycolysis in normal metabolic homeostasis, concerns arise
regarding potential adverse homeostatic consequences of
targeting specific glycolytic enzymes in a systemic manner
(Cheong et al., 2012). Selective cancer-associated expression
of specific isoforms of certain glycolytic enzymes could render
these enzymes potential selective targets for cancer therapy if
their expression is critical for the neoplastic phenotype. Among
all these potential targets, the hexokinase isoform, HK2, could
be an ideal target. HK2 is highly expressed in many cancers (Shi-
nohara et al., 1994), and although it is abundantly expressed in
embryonic tissues, it constitutes the predominant hexokinase
isoform in only a limited number of adult tissues. In contrast,
the HK1 isoform is ubiquitously expressed and constitutes the
major hexokinase in most normal adult tissues (Wilson, 1995,
2003).
Previous studies have demonstrated the ability of RNAi-medi-
ated HK2 silencing to inhibit tumor growth in a xenograft model
of glioblastoma (Wolf et al., 2011). However, it is unknown
whether these results can be extrapolated to other forms of
cancer, and the specific contributions of (and requirements for)
HK2 and the other major hexokinase isoform, HK1, in both tumor
initiation and maintenance are incompletely understood. In
addition, it is unknown whether systemic targeting of HK2 is a
viable approach to treating cancer. The, studies described here-
in provided a successful demonstration of systemic glycolytic
enzyme targeting for cancer therapy without adverse effects
on either metabolic homeostasis or life span.
Except for skeletal muscles, all other adult mouse tissues that
abundantly express HK2 also express relatively high levels of
HK1, which might play a compensatory or redundant role in
the absence of HK2. In addition, the ability of tissues, such as
myocardium and skeletal muscle, to utilize fatty acids as an alter-
nate energy substrate could buffer the metabolic impact of Hk2
deletion in these tissues (Felig and Wahren, 1975). Because the
deletion ofHk2 by the inducible Cre is not complete, it is possible
that the residual HK2 activity in skeletal muscles is sufficient toFigure 7. The Effect of Hk2 Deletion in KRasG12D NSCLC Cells on the In
(A) Steady state levels of glycolytic metabolites in LA2-1B and LA2-2 cells in the pr
Hk2/ (n = 5).
(B) Deletion of Hk2 results in a decreased fraction of 13C5 UTP and
13C5 AMP, A
(C) No significant change between the fraction of labeled lactate containing 13C1
(D) Contribution of glucose to the citrate/isocitrate, cis-aconitate, and acetyl CoA
(E) Total pools of TCA cycle metabolites were averaged across all four labeling co
with SE.
(F) The 13C5 or
13C4 LC/MS/MS peak areas upon U-
13C5 Gln feeding.
(G) Labeled 13C4 (upper panel) and
13C2 (bottom panel) succinate, malate, aspar
(H) Citrate/isocitrate pools from reductive carboxylation upon Hk2 deletion.
(I) AcCoA pools from reductive carboxylation upon Hk2 deletion.
(A–I) Unless otherwise noted, values are an average of n = 4 with SE, 2 hr pos
***p < 0.0005. See also Figure S5.maintain normal glucose homeostasis under resting conditions
and normal chow diet.
Notably, micewith 50%germline deletion ofHk2 do not have a
marked change in fed glucose levels under normal chow diet
(Heikkinen et al., 1999). However, they display hyperinsulinemia
under a high-fat diet and reduced endurance during exercise
(Fueger et al., 2003). Nonetheless, the possibility that the pheno-
type observed in mice with 50% germline deletion is exerted
through a developmental defect cannot be completely excluded.
Thus, adult mice with a conditional deletion of Hk2may not exert
these phenotypes.
Our studies showed that HK2 expression is exclusively
elevated in lung and breast cancers, whereas HK1 expression
did not change significantly. Although when overexpressed
HK1 can compensate for the loss of HK2 to some extent, we
found that the loss of HK2 was not followed by a compensatory
elevated expression of HK1. The underlying molecular basis for
selective HK2 overexpression in cancer cells is incompletely
understood, but this observation may relate to the fact that
HK1 is constitutively expressed in most normal tissues, whereas
HK2 is the principal inducible isoform (Robey and Hay, 2006).
Another plausible explanation for the selective induction of
HK2 expression in tumor cells is that it might bemore compatible
for the intrinsic properties of cancer cells. AlthoughHK1 andHK2
display very similar kinetics of metabolic activities some features
of HK2, which distinguish it from HK1, may render it more suited
to the versatile metabolic nature of cancer cells. For instance,
unlike HK1, which has a single active catalytic domain in its
carboxy-terminus, HK2 possesses two active catalytic domains
in its amino- and carboxy- termini. The two catalytic domains of
HK2 have different kinetics properties and thus may retain its
activity under conditions that are inhibitory for the single catalytic
domain of HK1 (Wilson, 2003).
TheContribution of HK2on theMetabolismof KRasG12D-
NSCLC Cells
Accumulating data suggest that the metabolites generated by
the branched pathways are much more critical for cancer cells
than glycolysis per se (Vander Heiden et al., 2009). Thesemetab-
olites are critical to support anabolic processes, such as nucleic
acids and lipid synthesis. Previous results showed that onco-
genic Ras elevates ribonucleotide synthesis largely through the
nonoxidative branch of the PPP (Ying et al., 2012). Our results
show that, in the absence of HK2, the diversion of glucose to
ribonucleotide synthesis through the nonoxidative branch oftracellular Levels of Metabolites Derived from Glucose or Glutamine
esence or absence of HK2. Data are presented as fold changes ofHk2f/f versus
DP, and ATP from the PPP upon U-13C6 glucose feeding.
, or relative contribution of the oxidative PPP, upon deletion of Hk2.
pools is decreased by Hk2 deletion, as observed by decreased 13C2 species.
nditions (U-12C6 Glc; U-
13C6 Glc; 1,2-
13C2 Glc; U-
13C5 Gln). Average of n = 16
tate, and citrate derived from glutamine.
t media switch. The p values for (A)–(I) are as follows: *p < 0.05, **p < 0.005,
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Figure 8. Schematic Illustration Depicting Metabolic Changes
Induced by Hk2 Deletion in KRasG12D-NSCLC Cells
Decreased flux is green; increased flux is red; maintained flux is gray. Dashed
arrows are predicted to be altered.
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the induction of HK2 expression by oncogenic Ras is critical
for the accelerated ribonucleotides synthesis. The results also
suggest that the diversion of glucose into the serine biosynthesis
pathway is reduced in the absence of HK2 (Figure 8). Metabolic
serine flux can be quite high in cancer cells where increased
serine biosynthesis has been appreciated for almost three
decades (Kalhan and Hanson, 2012). The levels and activities
of enzymes in this pathway are elevated in cancer cells and
found to be critical for cancer cells’ maintenance (Locasale
and Cantley, 2011; Possemato et al., 2011).
Finally, HK2 expression appears to be required for the efficient
flow of carbons from glycolysis onto the TCA cycle as mani-
fested by the reduced glucose derived acetyl-CoA and citrate,
which could also affect the diversion of glucose into fatty acid
synthesis (Figure 8). In cancer cells and oncogenic Ras-trans-
formed cells, TCA cycle intermediates, except citrate, are pre-
dominately derived from auxotrophic glutamine (DeBerardinis
et al., 2007; Gaglio et al., 2011). Hk2 deletion inhibits gluta-
mine-derived carbon utilization in anaplerosis (Figure 8), for a
reason that is not immediately clear to us. However, it is possible
that reduced glucose-derived citrate somehow contributes to
the attenuation of the flux from glutamine to other TCA cycle226 Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc.intermediates. This is also manifested by the increase in the re-
ductive carboxylation in the absence of HK2, possibly to com-
pensate for the lack of citrate derived from glycolysis (Figure 8).
In summary, HK2 plays a critical role in the diversion of glucose
into pathways, which are required for the anabolic activities in
cancer cells. Interestingly, it was shown and proposed previ-
ously that, in cancer cells, downstream glycolytic activities are
attenuated to divert glucose into the branched pathways. Our
results suggest that an increase in the most upstream step in
glucosemetabolism catalyzed by HK2 is also critical for diverting
glucose into these pathways in cancer cells. Therefore, this
could explain why cancer cells, in contrast to their normal coun-
terparts, express high levels of HK2. The expression of HK1 is
possibly sufficient for normal cell metabolism. The accelerated
anabolic metabolism in cancer cells demands a robust hexoki-
nase activity; therefore, the induction of HK2 expression is
required.
Future Implications for Cancer Therapy
Our studies placed HK2 as a selective therapeutic target for
NSCLC and breast cancer. Moreover, because it was shown
that breast cancer metastasis to the brain is significantly associ-
ated with high HK2 expression with poor patient survival (Pal-
mieri et al., 2009), it is possible that HK2 ablation would inhibit
metastasis.
We had previously shown that mitochondrial hexokinases,
HK1 and HK2, binding to mitochondria promotes cell survival
(Gottlob et al., 2001; Majewski et al., 2004). Thus, it is expected
that the ablation of HK2 would increase cell death. The results
presented here, however, show that the deficiency of HK2 exerts
cytostatic effect in vitro and in vivo. There are several possible
reasons why we did not observe an increase in cell death after
HK2 ablation. First, the cells also express HK1, which could be
sufficient to protect from cell death. Second, the experiments
were done with established cell lines in which Hk2 was either
deleted or was stably knocked down; thus, it is possible that,
during the establishment of the cell lines, cells in which HK2
was ablated beyond a certain threshold level were eliminated.
Supporting this possibility is the observation that, upon a
conditional knockdown of HK2, there was a significant increase
in cell death, although at low magnitude. Finally, we cannot
completely rule out an increase in cell death because it
might be technically difficult to observe low levels of cell death
in vivo, especially if the dead cells are phagocytosized. Never-
theless, it is possible that the deficiency of HK2 will render
cancer cells more susceptible to cell death by pro-apoptotic
drugs. Notably, investigations on drug resistance phenotypes
of breast cancer cells showed that upregulated glucose meta-
bolism, and especially HK2 expression, are associated with the
chemoresistance phenotypes in breast cancer cells (Kaplan
et al., 1990; Komurov et al., 2012; Lyon et al., 1988). Therefore,
HK2 may be a genetic modifier of drug resistance that can be
therapeutically exploited.
Taken together, our results provided strong rationales for
developing small-molecule inhibitors of HK2 for cancer therapy.
Perhaps the biggest challenge is to develop inhibitors that could
preferentially target HK2 and not HK1. Although HK1 and HK2
are very similar to each other, they exhibit some specific proper-
ties that could be exploited for isoform-specific inhibition. For
Cancer Cell
Hexokinase 2, Is a Therapeutic Target for Cancerinstance, both HK1 and HK2 are inhibited to the same extent by
their own product, G6P. However, inorganic phosphate antago-
nizes the inhibition of HK1 by G6P, whereas it increases the
inhibition of HK2 by G6P (Wilson, 2003). Because an increase
in intracellular inorganic phosphate is usually observed in high
glycolytic cells, such as cancer cells, this property of HK2 could
be exploited for the preferential inhibition of HK2 in cancer
therapy.
EXPERIMENTAL PROCEDURES
Mice Strains
Hexokinase 2 conditional knockout (Hk2flox/flox or Hk2f/f) mice were generated
as described in Figure S1A. KRas LSL-G12D and MMTV-Neu-IRES-Cre
(MMTVNIC) mice were described previously (Jackson et al., 2001; Ranger
et al., 2009). KRasLA2-G12D mice (Johnson et al., 2001) were obtained from
the NCI-Mouse Models of Human Cancer Consortium. UBCCreERT2 and
MMTVNeuT mice were purchased from The Jackson Laboratory. Generations
of other mice are detailed in Supplemental Information. All animal experiments
were approved by the University of Illinois at Chicago institutional animal care
and use committee.
Cell Lines
NCI-H460, NCI-H1299, NCI-H727, NCI-H358, T47D, MDA-MB-453, BT474,
LA2-1B, and LA2-2 cells were grown in RPMI-1640/10% FBS/1% pen-strep
media. MCF-10A cells were maintained in DMEM/F12 with the supplements.
MDA-MB-231, 293FT, phoenix-ecotropic cells, and MEFs were maintained
in DMEM/10% FBS/1% pen-strep media. All the cell lines were grown at
37C, 5% CO2 incubator unless otherwise mentioned.
Statistical Analysis
Statistical analysis was done with unpaired Student’s t tests, survival curves
were analyzed by log-rank test (Mantel-Cox), and data are expressed as SD
or SEM as indicated in the figure legend. Unless otherwise indicated, all the
experiments were performed for at least three times.
Other detailed experimental procedures are described in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.06.014.
ACKNOWLEDGMENTS
This work was supported by VA Merit Award BX000733, NIH grants
AG016927 and CA090764, in part by the University of Illinois at Chicago
Center for Clinical and Translational Sciences Award ULRR029879, and a
grant from the Chicago Biomedical Consortium with support from the Searle
Funds at the Chicago Community to N.H. K.C.P. was supported by DOD pre-
doctoral fellowship W81XWH-11-1-0006. We thank Shengfang Jin (Agios
Pharmaceuticals) for support and heroic efforts to coordinate the metabolo-
mics studies; Veronique Nogueira, Wan-Ni Yu, Xiao-ding Peng, Nilotpal
Roy, and other present and past N.H. laboratory members for various re-
agents, help, and suggestions; and Pradip Raychaudhuri (University of Illinois
at Chicago), Jonna Frasor (University of Illinois at Chicago), and Alejandro
Sweet-Cordero (Stanford University) for their generous gift of some of the
cell lines used in this study.
E.L.A., A.K..J., G.A.S., andM.F.C. are employees of Agios Pharmaceuticals.
Received: January 12, 2013
Revised: April 15, 2013
Accepted: June 18, 2013
Published: August 1, 2013REFERENCES
Cheong, H., Lu, C., Lindsten, T., and Thompson, C.B. (2012). Therapeutic tar-
gets in cancer cell metabolism and autophagy. Nat. Biotechnol. 30, 671–678.
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S.,
and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can
engage in glutamine metabolism that exceeds the requirement for protein and
nucleotide synthesis. Proc. Natl. Acad. Sci. USA 104, 19345–19350.
Felig, P., andWahren, J. (1975). Fuel homeostasis in exercise. N. Engl. J. Med.
293, 1078–1084.
Fueger, P.T., Heikkinen, S., Bracy, D.P., Malabanan, C.M., Pencek, R.R.,
Laakso, M., and Wasserman, D.H. (2003). Hexokinase II partial knockout im-
pairs exercise-stimulated glucose uptake in oxidative muscles of mice. Am.
J. Physiol. Endocrinol. Metab. 285, E958–E963.
Gaglio, D., Metallo, C.M., Gameiro, P.A., Hiller, K., Danna, L.S., Balestrieri, C.,
Alberghina, L., Stephanopoulos, G., and Chiaradonna, F. (2011). Oncogenic
K-Ras decouples glucose and glutamine metabolism to support cancer cell
growth. Mol. Syst. Biol. 7, 523.
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R.B., and Hay, N.
(2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first
committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15,
1406–1418.
Heikkinen, S., Pietila¨, M., Halmekyto¨, M., Suppola, S., Pirinen, E., Deeb, S.S.,
Ja¨nne, J., and Laakso, M. (1999). Hexokinase II-deficient mice: prenatal death
of homozygotes without disturbances in glucose tolerance in heterozygotes.
J. Biol. Chem. 274, 22517–22523.
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R.,
Jacks, T., and Tuveson, D.A. (2001). Analysis of lung tumor initiation and pro-
gression using conditional expression of oncogenic K-ras. Genes Dev. 15,
3243–3248.
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson,
D.A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes
early onset lung cancer in mice. Nature 410, 1111–1116.
Kalhan, S.C., and Hanson, R.W. (2012). Resurgence of serine: an often
neglected but indispensable amino Acid. J. Biol. Chem. 287, 19786–19791.
Kaplan, O., Navon, G., Lyon, R.C., Faustino, P.J., Straka, E.J., and Cohen, J.S.
(1990). Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human
breast cancer cells: toxicity and magnetic resonance spectroscopy studies of
metabolism. Cancer Res. 50, 544–551.
Komurov, K., Tseng, J.T., Muller, M., Seviour, E.G., Moss, T.J., Yang, L.,
Nagrath, D., and Ram, P.T. (2012). The glucose-deprivation network counter-
acts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Mol. Syst. Biol. 8, 596.
Lee, W.N., Boros, L.G., Puigjaner, J., Bassilian, S., Lim, S., and Cascante, M.
(1998). Mass isotopomer study of the nonoxidative pathways of the pentose
cycle with [1,2-13C2]glucose. Am. J. Physiol. 274, E843–E851.
Locasale, J.W., and Cantley, L.C. (2011). Genetic selection for enhanced
serine metabolism in cancer development. Cell Cycle 10, 3812–3813.
Lunt, S.Y., and Vander Heiden, M.G. (2011). Aerobic glycolysis: meeting the
metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27,
441–464.
Lyon, R.C., Cohen, J.S., Faustino, P.J., Megnin, F., and Myers, C.E. (1988).
Glucose metabolism in drug-sensitive and drug-resistant human breast can-
cer cells monitored by magnetic resonance spectroscopy. Cancer Res. 48,
870–877.
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P.E., Skeen, J.E., Gottlob, K.,
Chandel, N.S., Thompson, C.B., Robey, R.B., and Hay, N. (2004).
Hexokinase-mitochondria interaction mediated by Akt is required to inhibit
apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16, 819–830.
Mathupala, S.P., Rempel, A., and Pedersen, P.L. (2001). Glucose catabolism in
cancer cells: identification and characterization of a marked activation
response of the type II hexokinase gene to hypoxic conditions. J. Biol.
Chem. 276, 43407–43412.Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc. 227
Cancer Cell
Hexokinase 2, Is a Therapeutic Target for CancerMuller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988).
Single-step induction of mammary adenocarcinoma in transgenic mice
bearing the activated c-neu oncogene. Cell 54, 105–115.
Owen, O.E., Kalhan, S.C., and Hanson, R.W. (2002). The key role of anaplero-
sis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277, 30409–
30412.
Palmieri, D., Fitzgerald, D., Shreeve, S.M., Hua, E., Bronder, J.L., Weil, R.J.,
Davis, S., Stark, A.M., Merino, M.J., Kurek, R., et al. (2009). Analyses of
resected human brain metastases of breast cancer reveal the association
between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer
Res. 7, 1438–1445.
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K.,
Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011).
Functional genomics reveal that the serine synthesis pathway is essential in
breast cancer. Nature 476, 346–350.
Ranger, J.J., Levy, D.E., Shahalizadeh, S., Hallett, M., and Muller, W.J. (2009).
Identification of a Stat3-dependent transcription regulatory network involved
in metastatic progression. Cancer Res. 69, 6823–6830.
Robey, R.B., and Hay, N. (2006). Mitochondrial hexokinases, novel mediators
of the antiapoptotic effects of growth factors and Akt. Oncogene 25, 4683–
4696.
Robey, R.B., and Hay, N. (2009). Is Akt the ‘‘Warburg kinase’’? Akt-energy
metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25–31.
Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis,
G., Zediak, V.P., Velez, M., Bhandoola, A., and Brown, E.J. (2007). Deletion of
the developmentally essential gene ATR in adult mice leads to age-related
phenotypes and stem cell loss. Cell Stem Cell 1, 113–126.
Schulze, A., and Harris, A.L. (2012). How cancer metabolism is tuned for pro-
liferation and vulnerable to disruption. Nature 491, 364–373.
Shedden, K., Taylor, J.M., Enkemann, S.A., Tsao, M.S., Yeatman, T.J., Gerald,
W.L., Eschrich, S., Jurisica, I., Giordano, T.J., Misek, D.E., et al.; Director’s228 Cancer Cell 24, 213–228, August 12, 2013 ª2013 Elsevier Inc.Challenge Consortium for the Molecular Classification of Lung
Adenocarcinoma. (2008). Gene expression-based survival prediction in lung
adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14,
822–827.
Shinohara, Y., Yamamoto, K., Kogure, K., Ichihara, J., and Terada, H. (1994).
Steady state transcript levels of the type II hexokinase and type 1 glucose
transporter in human tumor cell lines. Cancer Lett. 82, 27–32.
Ursini-Siegel, J., Hardy, W.R., Zuo, D., Lam, S.H., Sanguin-Gendreau, V.,
Cardiff, R.D., Pawson, T., and Muller, W.J. (2008). ShcA signalling is essential
for tumour progression in mousemodels of human breast cancer. EMBO J. 27,
910–920.
van de Vijver, M.J., He, Y.D., van’t Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W.,
Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., et al. (2002). A gene-
expression signature as a predictor of survival in breast cancer. N. Engl. J.
Med. 347, 1999–2009.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009).
Understanding the Warburg effect: the metabolic requirements of cell prolifer-
ation. Science 324, 1029–1033.
Wilson, J.E. (1995). Hexokinases. Rev. Physiol. Biochem. Pharmacol. 126,
65–198.
Wilson, J.E. (2003). Isozymes of mammalian hexokinase: structure, subcellular
localization and metabolic function. J. Exp. Biol. 206, 2049–2057.
Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R.,
Hawkins, C., and Guha, A. (2011). Hexokinase 2 is a key mediator of aerobic
glycolysis and promotes tumor growth in human glioblastoma multiforme.
J. Exp. Med. 208, 313–326.
Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-
Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. (2012).
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic
glucose metabolism. Cell 149, 656–670.
